Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 17/09/2024 pm IST			5-day change	1st Jan Change
903.40 ^DKK	-2.03%		+1.85%	+29.41%

01:16am	Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports	RE
17/09	Health Care Down as Novo Nordisk Slides on Drug-Price Fears - Health Care Roundup	DJ

NOVO NORDISK : UBS sticks Neutral

August 09, 2024 at 11:53 am IST

UBS's research confirms his advice and maintains his neutral opinion on the stock. The target price continues to be set at DKK 1100.

Latest news about Novo Nordisk A/S

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports	04:46am	RE
Health Care Down as Novo Nordisk Slides on Drug-Price Fears - Health Care Roundup	18/09	DJ
Sector Update: Health Care Stocks Retreat Late Afternoon	18/09	MT
Sector Update: Health Care	18/09	MT
Novo Nordisk's Ozempic Likely to Face U.S. Price Negotiations, Bloomberg Reports	17/09	DJ
US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month	17/09	RE
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations	17/09	MT
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations, Bloomberg Reports	17/09	MT
Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines	16/09	MT
Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates	16/09	CI
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	13/09	RE
NOVO NORDISK : Deutsche Bank keeps its Buy rating	12/09	ZD
Roche shares drop on side effects result in early-stage obesity pill trial	12/09	RE
Health Care Down on Cyclical Bias -- Health Care Roundup	12/09	DJ
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday	11/09	MT
Novo Nordisk's Experimental Obesity Pill Could Be More Effective With Extended Use	11/09	DJ
NOVO NORDISK : JP Morgan reiterates its Buy rating	11/09	ZD
NOVO NORDISK : Gets a Neutral rating from UBS	11/09	ZD
Novo Nordisk Reports Positive Results of Phase 3a Trial of Anti-Obesity Drug Liraglutide in Children	11/09	MT
Health Care Up on Defensive Bias -- Health Care Roundup	11/09	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	11/09	RE
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	06/09	MT
Novo Nordisk to present advances in diabetes treatment	06/09	CF
Are thematic ETFs useless?	06/09
Veeva Systems: leader in cloud solutions for the life sciences industry	06/09

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Employees

69,260

Sector

Pharmaceuticals

Calendar

06/11/2024 - Q3 2024 Earnings Release

More about the company